Goji Berry

Metadata

Approved Indications

Commission E (Germany)

• No Commission E monograph. Goji berry was not part of the European phytotherapy tradition at the time of Commission E evaluations and has not been assessed subsequently.

ESCOP

• No ESCOP monograph for Lycium barbarum.

EMA/HMPC

• No HMPC assessment or monograph initiated. Lycium barbarum is not listed on the HMPC work program. As with other TCM-origin herbs, the EU traditional use pathway (requiring 30 years of documented use in Europe, including 15 years within the EU) presents a structural barrier to regulatory recognition.

Chinese Pharmacopoeia

• Listed: Gou Qi Zi is an official drug in the Pharmacopoeia of the People’s Republic of China (2020 edition), with a history of use dating back over 2,300 years.
• Traditional indications: Nourishing Liver and Kidney yin; replenishing Jing (essence); brightening the eyes. Used for Liver and Kidney yin deficiency manifesting as dizziness, blurred vision, diminished visual acuity, sore lumbar region and knees, seminal emission, and consumption-related thirst.
• Official dose: 6-12 g dried fruit per day.
• Classification: Listed in the Shennong Bencao Jing (Divine Farmer’s Classic of Materia Medica, ~200 CE) as an upper-grade herb suitable for long-term use to promote longevity.

Novel Food Status (EU)

• Not classified as a Novel Food. Lycium barbarum fruit was already consumed in Europe prior to the introduction of the Novel Food Regulation (EC) No 258/97 in 1997, and therefore does not fall under Novel Food legislation. The EU Novel Food Catalogue specifically lists Lycium barbarum as an approved food ingredient. Note: this applies only to L. barbarum, not to other Lycium species such as L. chinense.

Agreement/Disagreement

• Regulatory gap: Goji berry has robust pharmacopoeial recognition in China and widespread use as a food and supplement globally, but zero regulatory recognition as a therapeutic agent in Europe. This reflects the EU framework’s structural difficulty in accommodating non-European traditional medicines rather than any judgment on the herb’s merit. The food-supplement distinction is important: goji berry is freely sold as a food in Europe but cannot make medicinal claims.

Conditions Treated

TCM Traditional Indications (Documented)

• Liver and Kidney yin deficiency: Dizziness, blurred vision, tinnitus, sore lower back and knees
• Brightening the eyes (Ming Mu): Diminished visual acuity, dry eyes, blurred vision — one of the most classical eye-nourishing herbs in TCM
• Jing (essence) deficiency: Premature aging, gray hair, seminal emission, infertility
• Lung yin deficiency: Dry cough, consumptive thirst (Xiao Ke, corresponding to diabetic symptoms)
• General longevity tonic: Traditionally combined with Chrysanthemum (Ju Hua) for eye health, or with Rehmannia (Shu Di Huang) and Cornus (Shan Zhu Yu) for Kidney yin nourishment

Modern/Western Research Indications

• Immune support and enhancement: LBP-mediated immunomodulation; enhancement of innate and adaptive immune parameters (preclinical and limited clinical evidence)
• Eye health / macular protection: Rich zeaxanthin source; increased macular pigment optical density (MPOD) in two RCTs; potential protection against age-related macular degeneration (AMD)
• Antioxidant support: Improved in vivo antioxidant biomarkers (SOD, GSH-Px) and reduced lipid peroxidation (MDA) in clinical trial
• General wellbeing and vitality: Improved subjective ratings of energy, sleep quality, mental acuity in RCT
• Anti-aging: Preclinical evidence for telomere protection, inhibition of cellular senescence (LBP inhibits p53/p21/Bax, upregulates Mdm2 and TERT); clinical relevance unestablished
• Neuroprotection: Preclinical evidence for protection against neurodegeneration; clinical translation pending
• Glucose and lipid metabolism: Preclinical evidence for improved insulin sensitivity (GLUT4 translocation, PI3K/Akt pathway); meta-analysis of animal studies supportive but human data limited

Mechanism of Action

Active Compounds

Immune Mechanisms (LBP-mediated)

1. Dendritic cell maturation: LBP activates TLR2 and TLR4 on dendritic cells, triggering MyD88-NF-kB and p38 MAPK signaling cascades. This promotes phenotypic and functional maturation of dendritic cells, enhancing antigen presentation and T lymphocyte priming. (PMID: 23904044, PMID: 17289406)
2. Macrophage activation: LBP enhances macrophage phagocytosis, nitric oxide production, and secretion of pro-inflammatory cytokines (IL-6, IL-12, TNF-alpha), with maximal effect at concentrations around 100 microg/mL. (PMID: 32188121)
3. T cell and NK cell activation: LBP restores T lymphocyte subsets in immunosuppressed models (cyclophosphamide-treated mice), increases CD4+ and CD8+ T cell counts, and enhances NK cell cytotoxicity. (PMID: 34421857)
4. Cytokine production: Promotes secretion of IL-2, IL-6, IL-12, IFN-gamma, and TNF-alpha. Molecular weight of LBP influences potency: medium MW fractions (100-300 kDa) exhibit highest TLR4 binding affinity and cytokine-inducing activity.
5. Gut microbiota modulation: LBP acts as a prebiotic, promoting growth of Bifidobacterium and Lactobacillus, modulating gut microbiota composition and increasing short-chain fatty acid production, indirectly supporting systemic immune function. (PMC5968096)

Macular Protection Mechanism

• Zeaxanthin dipalmitate in goji berries is hydrolyzed during digestion to free zeaxanthin, which is absorbed and selectively deposited in the macular region of the retina as macular pigment.
• Zeaxanthin and its isomer meso-zeaxanthin are the dominant carotenoids in the foveal center, where they filter high-energy blue light and quench reactive oxygen species, protecting photoreceptors and retinal pigment epithelium from oxidative damage.
• Goji berries are among the richest known dietary sources of zeaxanthin, with dried fruit containing 0.5-1.2 mg/g dry weight, predominantly as zeaxanthin dipalmitate (~80% of total carotenoids). (PMID: 25496337)

Antioxidant and Anti-aging Mechanisms

• LBP enhances endogenous antioxidant defenses by upregulating superoxide dismutase (SOD), catalase, and glutathione peroxidase (GSH-Px).
• Anti-aging effects: LBP inhibits cell apoptosis and senescence by decreasing expression of p53, p21, and Bax while increasing expression of Mdm2 and TERT (telomerase reverse transcriptase). (PMID: 25552899)
• Neuroprotection: LBP activates PI3K/Akt/Nrf2 pathway, promoting neuronal survival under oxidative stress conditions.

Clinical Evidence Summary

Clinical evidence for goji berry is limited but growing. Most trials are small, short-term, and from a small number of research groups. No Cochrane reviews or large-scale meta-analyses exist.

Eye Health Trials (Macular Pigment)

Immune Function and Antioxidant Trials

Evidence Limitations

• Most published clinical trials used proprietary GoChi product, limiting generalizability to other goji berry forms.
• Sample sizes are small (n=27-150), treatment durations are short (14-90 days).
• Several trials originate from the same research group (Amagase et al.), raising concerns about independent replication.
• Outcome measures are often subjective (questionnaire-based wellbeing scores) or surrogate biomarkers rather than hard clinical endpoints.
• No Cochrane systematic review or large-scale independent RCT exists for any indication.
• Preclinical evidence (in vitro and animal studies on LBP) is extensive and compelling, but the translation gap to clinical validation remains the central challenge, as with astragalus and reishi.

Safety Profile

General Assessment

Goji berries have been consumed as a food and medicine in China for over 2,000 years and are generally considered well-tolerated. Up to 15 g/day of dried fruit has been used safely for up to 4 months in clinical trials. No serious adverse events have been reported in controlled studies.

Contraindications

• Warfarin/anticoagulant therapy: CRITICAL contraindication. Multiple case reports of clinically significant interaction (see Drug Interactions below). Patients on warfarin or other anticoagulants should avoid goji berry consumption.
• Known allergy to Solanaceae: Goji berry belongs to the Solanaceae (nightshade) family. Cross-reactivity with lipid transfer protein (LTP) allergens from other foods (peach, tomato, peanut) has been documented. (PMID: 23101309)
• Autoimmune disease: As with all immunomodulators, theoretical concern about stimulating autoimmune pathways due to LBP-mediated immune enhancement.

Drug Interactions

Warfarin (CRITICAL)

This is the most clinically important and well-documented drug interaction for goji berry. Multiple case reports have established a probable interaction:

• Rivera et al. (2012): A 71-year-old woman on stable warfarin therapy was hospitalized with a markedly elevated, indeterminate INR (prothrombin time >120 seconds) after consuming goji berry juice for 4 days. She presented with epistaxis, bruising, and rectal bleeding. After discontinuation of goji juice and warfarin, treatment with phytonadione (vitamin K) returned INR to 2.6 over 2 days. The Naranjo adverse drug reaction probability scale indicated a “probable” relationship (score of 6). (PMID: 22392461)

• Leung et al. (2017): A 65-year-old Chinese man on stable warfarin therapy experienced elevated INR with associated bleeding after drinking Gouqizi (goji berry) wine. The authors concluded that large doses (>6-12 g) of Gouqizi can significantly enhance the anticoagulant action of warfarin. (PMID: 28962463)

• Mechanism: In vitro studies demonstrate that goji berry extracts, particularly the polyphenolic fraction, strongly inhibit CYP2C9 (IC50 = 0.048 mg/mL), the primary enzyme responsible for warfarin metabolism. Both fresh juice and commercial juice preparations caused >75% inhibition of CYP2C9 activity. Ethanol extracts showed the strongest inhibition (>90% inhibition of CYP2C9 and CYP2C19). (PMID: 27352447)

• Clinical significance: This interaction is well-documented and potentially life-threatening. Patients taking warfarin should be advised to avoid goji berry in all forms (dried fruit, juice, wine, tea, supplements).

Other Drug Interactions

• Other CYP2C9 substrates: Goji berry may increase plasma concentrations of drugs metabolized by CYP2C9, including NSAIDs (diclofenac, ibuprofen), sulfonylureas (glipizide, glyburide), losartan, and phenytoin. Clinical significance uncertain but caution is advised.
• CYP3A4 substrates: In vitro inhibition of CYP3A4 has been demonstrated (polyphenolic fraction IC50 = 0.119 mg/mL). Potential interaction with narrow therapeutic index CYP3A4 substrates (cyclosporine, tacrolimus, some statins). (PMID: 27352447)
• Antidiabetic agents: Goji berry may have additive blood sugar-lowering effects; theoretical risk of hypoglycemia when combined with insulin or oral hypoglycemics.
• Antihypertensive agents: Additive hypotensive effects have been reported in preclinical studies.
• Flecainide: A case report documented flecainide toxicity associated with goji berry use, potentially mediated by CYP enzyme inhibition. (PMC8167332)

Allergic Reactions

• Allergic reactions to goji berries are uncommon but increasingly reported as consumption has become widespread in Western countries.
• Cross-reactivity with lipid transfer protein (LTP) from other foods (peach, tomato, peanut) has been documented. Sensitization prevalence in Spain was 6% by skin prick testing. (PMID: 23101309)
• Anaphylaxis following goji berry ingestion has been reported in at least two allergic patients. (PMID: 22312943)
• One case of systemic photosensitivity attributed to goji berries has been reported.
• Individuals with known LTP allergy or Solanaceae allergy should exercise caution.

Side Effects (at recommended doses)

• Common: Generally very well-tolerated. Occasional mild gastrointestinal symptoms (bloating, nausea).
• Uncommon: Allergic reactions (urticaria, pruritus) in sensitized individuals.
• Rare: Anaphylaxis (in LTP-allergic individuals), photosensitivity.

Pregnancy and Lactation

• Pregnancy: Insufficient human safety data. Goji berry contains betaine, which has been associated with uterotonic activity in some preclinical models. Traditional TCM sources generally consider goji berry safe in pregnancy at food-level doses, but this has not been confirmed in controlled studies. Exercise caution and consult a healthcare provider.
• Lactation: Traditional use during postpartum period in TCM, but no controlled safety data. Consult a healthcare provider.

Clinical Dosage

Dried Fruit (Traditional TCM)

• Standard dose: 6-12 g/day (Chinese Pharmacopoeia), up to 15 g/day in some sources
• Preparation: Eaten directly as dried fruit, or simmered in decoction for 20-30 minutes (traditional method); also added to soups, porridge, and teas
• Eye health trials: 25-28 g/day dried berries (Cheng et al. 2018; Li et al. 2021)
• Note: Higher doses used in clinical trials (25-28 g/day) significantly exceed the Chinese Pharmacopoeia dose and should be used with awareness of potential drug interactions

Standardized Extract / Juice

• GoChi (standardized juice): 120 mL/day (clinical trial dose; Amagase & Nance 2008)
• LBP extract: Doses vary by product; clinical studies have used preparations standardized to polysaccharide content
• Lacto-wolfberry formulation: 13.7 g/day in milk-based preparation (Bucheli et al. 2011)

Tincture

• Standard dose: 2-4 mL of 1:5 tincture, taken 2-3 times daily

Granulated / Powdered Herb

• Standard dose: 6-18 g daily equivalent dried herb as infusion or decoction

Duration

• TCM tradition supports long-term use as a tonic (weeks to months to years).
• Clinical trials have used durations of 14-90 days.
• No upper duration limit established in safety studies at food-level doses.
• CRITICAL: Patients on warfarin or other CYP2C9-metabolized medications should avoid all forms regardless of dose or duration.

Sources

• Amagase H, Nance DM. A randomized, double-blind, placebo-controlled, clinical study of the general effects of a standardized Lycium barbarum (Goji) Juice, GoChi. J Altern Complement Med. 2008;14(4):403-412. (PMID: 18447631)
• Amagase H, Sun B, Borek C. Lycium barbarum (goji) juice improves in vivo antioxidant biomarkers in serum of healthy adults. Nutr Res. 2009;29(1):19-25. (PMID: 19185773)
• Rivera CA, Ferro CL, Bursua AJ, Gerber BS. Probable interaction between Lycium barbarum (goji) and warfarin. Pharmacotherapy. 2012;32(3):e50-53. (PMID: 22392461)
• Leung H, Hung A, Hui AC, Chan TY. Bleeding due to a probable interaction between warfarin and Gouqizi (Lycium Barbarum L.). Toxicol Rep. 2017;4:601-602. (PMID: 28962463)
• Georgiev KD, Slavov IJ, Iliev IA. In vitro activity of Lycium barbarum (Goji) against major human phase I metabolism enzymes. J Complement Integr Med. 2016;13(4):349-353. (PMID: 27352447)
• Li X, Holt RR, Keen CL, Morse LS, Yiu G, Hackman RM. Goji Berry Intake Increases Macular Pigment Optical Density in Healthy Adults: A Randomized Pilot Trial. Nutrients. 2021;13(12):4409. (PMID: 34959963)
• Cheng CY, Chung WY, Szeto YT, Benzie IF. Macular pigment and serum zeaxanthin levels with Goji berry supplement in early age-related macular degeneration. Int J Ophthalmol. 2018;11(6):978-982. (PMID: 29977809)
• Bucheli P, Vidal K, Shen L, et al. Goji berry effects on macular characteristics and plasma antioxidant levels. Optom Vis Sci. 2011;88(2):257-262. (PMID: 21169874)
• Larramendi CH, Garcia-Abujeta JL, Vicario S, et al. Goji berries (Lycium barbarum): risk of allergic reactions in individuals with food allergy. J Investig Allergol Clin Immunol. 2012;22(5):345-350. (PMID: 23101309)
• Cariglia M, Ferrazzano GF, Cifani C, et al. Anaphylaxis associated with the ingestion of Goji berries (Lycium barbarum). Ann Allergy Asthma Immunol. 2012;108(2):132-133. (PMID: 22312943)
• Inbaraj BS, Lu H, Hung CF, Wu WB, Lin CL, Chen BH. Determination of carotenoids and their esters in fruits of Lycium barbarum Linnaeus by HPLC-DAD-APCI-MS. J Pharm Biomed Anal. 2008;47(4-5):812-818. (PMID: 25496337 — validated method for zeaxanthin dipalmitate analysis)
• Potterat O. Goji (Lycium barbarum and L. chinense): Phytochemistry, pharmacology and safety in the perspective of traditional uses and recent popularity. Planta Med. 2010;76(1):7-19. (PMID: 19844860)
• Cheng J, Zhou ZW, Sheng HP, et al. An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides. Drug Des Devel Ther. 2015;9:33-78. (PMID: 25552899)
• Zhu J, Liu W, Yu J, et al. Characterization and hypoglycemic effect of a polysaccharide extracted from the fruit of Lycium barbarum L. Carbohydr Polym. 2013;98(1):8-16.
• Bo R, Zheng S, Xing J, et al. Lycium barbarum polysaccharides induce Toll-like receptor 2- and 4-mediated phenotypic and functional maturation of murine dendritic cells via activation of NF-kappaB. Mol Med Rep. 2016;14(4):3321-3327. (PMID: 23904044)
• Zhu CP, Zhang SH. Lycium barbarum polysaccharide inhibits the proliferation of HeLa cells by inducing apoptosis. J Sci Food Agric. 2013;93(1):149-156.
• Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. Vol 1. 2020 Edition.
• Chang RC, So KF. Use of anti-aging herbal medicine, Lycium barbarum, against aging-associated diseases. What do we know so far? Cell Mol Neurobiol. 2008;28(5):643-652.
• Kulczyński B, Gramza-Michałowska A. Goji Berry (Lycium barbarum): Composition and Health Effects — a Review. Pol J Food Nutr Sci. 2016;66(2):67-75.

Connections

• Astragalus: Both are foundational TCM tonic herbs (Huang Qi and Gou Qi Zi); frequently combined in formulas for Qi and Yin deficiency; both rely on polysaccharide fractions for immunomodulation; both lack European regulatory recognition
• Reishi: Both are iconic East Asian tonic medicines with polysaccharide-driven immune mechanisms; reishi has more clinical evidence for cancer adjunctive therapy, while goji has stronger eye health evidence
• Elderberry: Both used for immune support; elderberry has stronger clinical evidence for acute viral infections, while goji is a long-term tonic; both have documented drug interactions
• Bilberry: Both used for eye health; bilberry provides anthocyanins for retinal microcirculation, while goji provides zeaxanthin for macular pigment — complementary mechanisms of retinal protection
• Schisandra: Both are TCM tonic berries; schisandra nourishes all five Yin organs while goji specifically targets Liver and Kidney yin; both have hepatoprotective properties (schisandra via lignans, goji via betaine and cerebrosides)